DrugPatentWatch Archives
Click here to return to the current data set
|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,400 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: TEGRETOL-XR
Summary for Tradename: TEGRETOL-XR
|
| Pharmacology for Tradename: TEGRETOL-XR
| ||||||||||||
Clinical Trials for: TEGRETOL-XRCarbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency Status: Recruiting Condition: Alpha-1-antitrypsin Deficiency; Liver Cirrhosis Carbamazepine Extended-Release for the Treatment of Bipolar Depression Status: Completed Condition: Bipolar Depression A Study to Investigate the Potential Pharmacokinetic Interactions Between Phenytoin or Carbamazepine and Telaprevir Status: Completed Condition: Healthy Participants Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania Status: Completed Condition: Bipolar Disorder A Study of the Pharmacokinetics (PK) and Safety of IV Carbamazepine Relative to Oral Carbamazepine in Adults With Epilepsy Status: Completed Condition: Epilepsy Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for Rapid Cycling Bipolar Disorder Status: Active, not recruiting Condition: Bipolar Disorder Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia Status: Completed Condition: Trigeminal Neuralgia Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy Status: Completed Condition: Epilepsy Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies Status: Completed Condition: Epilepsy Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older Status: Recruiting Condition: Epilepsy; Monotherapy Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Patent Expiration | Exclusivity Expiration | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | TEGRETOL-XR | carbamazepine | TABLET, EXTENDED RELEASE; ORAL | 020234 | Mar 25, 1996 | RX | No | 5,284,662 | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novartis | TEGRETOL-XR | carbamazepine | TABLET, EXTENDED RELEASE; ORAL | 020234 | Mar 25, 1996 | RX | No | RE34990 | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novartis | TEGRETOL-XR | carbamazepine | TABLET, EXTENDED RELEASE; ORAL | 020234 | Mar 25, 1996 | RX | Yes | 5,284,662 | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novartis | TEGRETOL-XR | carbamazepine | TABLET, EXTENDED RELEASE; ORAL | 020234 | Mar 25, 1996 | RX | Yes | RE34990 | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: TEGRETOL-XR
| Drugname | Dosage | Strength | RLD | Submissiondate |
| carbamazepine | Extended-release Tablets | 100 mg | Tegretol-XR | 12/30/2005 |
« Back to Dashboard
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc
